References - - BioPharm International



BioPharm International

ARTICLESBiopharmaceutical Process Extractables Core Team. Evaluation of extractables from product-contact surfaces. BioPharm International 2002; 15(12):22-34.

Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003; 20(9):1325-1336.

Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993; 10:307-377.

Crowe JH, Crowe LM, Carpenter JF. Preserving dry biomaterials: the water replacement hypothesis, part 1. BioPharm 1993; 6(3):28.

Crowe JH, Crowe LM, Carpenter JF. Preserving dry biomaterials: the water replacement hypothesis, part 2. BioPharm 1993; 6(4):40.

Faulkner J. The evolving role of product characterization during development.BioPharm 2000; 13(6):26.

Franks F, Hatley RHM, Mathias SF. Materials science and the production of shelf-stable biologicals. BioPharm 1991; 4(8):38.

Imensek M. Sterile fill facilities: problems and resolutions. BioPharm International 2003; 16(9):44-54.

Katre N. Lipid-based multivesicular carriers for sustained delivery of therapeutic proteins and peptides. BioPharm International 2001; 14(3 supplement):8.

Kerr AP, et al. An early warning tool for pharmaceutical development. BioPharm 1992; 5(2):24.

Kleinert HD, Baker WR, Stein HH. Orally bioavailable peptidelike molecules: a case history. BioPharm 1993; 6(1):36.

Krishnamurthy R. Protein stability in pulmonary delivery formulations: a review. BioPharm 1999; 12(3):34.

Krishnamurthy R, Manning MC. The stability factor: importance in formulation development. Curr Pharm Biotech 2002; 3:361-371.

Lakings DB. Making a successful transition from drug discovery to drug development, part 1. BioPharm 1995; 8(7):20.

Lee VHL. Oral route of peptide and protein drug delivery. BioPharm 1992; 5(5):39.

Lee VHL. Trends in peptide and protein drug delivery. BioPharm1991; 4(2):22.

Lee WA, Longenecker JP. Intranasal delivery of proteins and peptides. BioPharm 1988; 1(3):30.

Lee WA. Permeation enhancers for the nasal delivery of protein and peptide therapeutics. BioPharm 1990; 3(9):22.

Patapoff TW, Overcashier DE. The importance of freezing on lyophilization cycle development. BioPharm 2002; 15(3):16-21, 72.

Pelegrin M, et al. Encapsulated antibody-producing cells for long-term passive immunotherapy. BioPharm 1999; 12(10):32.

Pikal MJ. Freeze-drying of proteins, part 2: formulation selection. BioPharm 1990; 3(8):26.

Roser B. Trehalose drying: a novel replacement for freeze-drying. BioPharm 1991; 4(7):47.

Sanghvi P, Banakar UV. Ultrasonics: principles and biomedical applications. BioPharm 1991; 4(7):32.

Schmidt DJ, Akers MJ. Cryogranulation: a potential new final process for bulk drug substances. BioPharm 1997; 10(4):28.

Scott C. Formulation case studies: a tutorial. BioPharm 2001; 14(8):34-35.

Strattan CE. Cyclodextrins and biological macromolecules. BioPharm 1991; 4(9):44.

Talsma H, Crommelin DJA. Liposomes as drug delivery systems, part 2: characterization. BioPharm 1992; 5(9):38.

Talsma H, Crommelin DJA. Liposomes as drug delivery systems, part 3: stabilization. BioPharm 1993; 6(2):40.

Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. Freezing bulk-scale biopharmaceuticals using common techniques — and the magnitude of freeze-concentration. BioPharm 2002; 15(5):22-34.

Weiner AL. Developing lipid-based vehicles for peptide and protein drugs. BioPharm 1990; 3(2):27.

Weiner AL. Lipid-based vehicles for peptide and protein drugs, part 2: manufacturing variables. BioPharm 1990; 3(3):16.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here